Viral hepatitis C

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 12, 2008, Pages 734-740

  Czepiel, Jacek ^a   Biesiada, Grazyna ^a   Mach, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Epidemiology; Pathogenesis; Treatment; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ALOPECIA; CLINICAL FEATURE; COUGHING; DEPRESSION; DISEASE COURSE; DISEASE TRANSMISSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLU LIKE SYNDROME; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INFECTION PREVENTION; INSOMNIA; LEUKOPENIA; LIVER CIRRHOSIS; MORTALITY; PREVALENCE; PRURITUS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URIC ACID BLOOD LEVEL;

EID: 58449092843     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Juszczyk J. [Viral hepatitis type C]. In: Dziubek Z, ed. [Viral hepatitis]. Warszawa, PZWL, 2000: 277-287. Polish.
2. Memon Ml, Memon MA. Hepatitis C: an epidemiological review. J Viral Hepat. 2002: 9: 84-100.
3. Juszczyk J. [Hepatitis C - Handbook of diagnostics and antiviral treatment]. Poznan, Termedia, 2003. Polish.
4. Afdhal NH. The natural history of hepatitis C. Sem Liv Dis. 2004: 24: 3-8.
5. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005; 11: 286-295.
6. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5: 558-567.
7. Bellentani S, Miglioli L, Bedogni G. Epidemiology of hepatitis C virus infection. Minerva Gastroenterol Dietol. 2005; 51:15-29.
8. Herrine SK, Rossi S, Navarro VJ. Management of patients with chronic hepatitis C infection. Clin Exp Med. 2006; 6: 20-26.
9. Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006; 8: 53-59.
10. Vento S, Nobili V, Cainelli F. Clinical course of infection with hepatitis C.Br Med J. 2006; 18: 374-375.
11. Freeman AJ, Law MG, Kaldor JM, et al. Predicting to cirrhosis in chronic hepatitis C virus infection. J Vir Hepat. 2003; 10: 285-293.
12. Poynard T, Yuen M, Ratziu V. et al. Viral hepatitis C. Lancet. 2003. 362: 2095-2100.
13. Ferreira-Gonzalez A, Shiftman ML: Use of diagnostic testing for managing hepatitis C virus infection. Sem Liv Dis. 2004; 24: 9-18.
14. Jerome KR, Gretch DR. Laboratory approaches to the diagnosis of hepatitis C virus infection. Minerva Gastroenterol Dietol. 2004; 50: 9-20.
15. D'Souza R, Foster GR. Diagnosis and treatment of hepatitis C. J R Soc Med. 2004; 97: 223-225.
16. Cielecka-Kuszyk J, Pawfowska J. [Histological examination in chronic viral hepatitis: classification, assessment of grade of inflammatory changes activity and fibrosis]. Hepatol Pol. 1997; 4: 37-41. Polish.
17. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995; 19:1409-1417.
18. Fried MW, Hadziyannis MD. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Sem Liv Dis. 2004; 24: 47-54.
19. Kim Al, Saab S. Treatment of hepatitis C. Am J Med. 2005; 118: 808-815.
20. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat. 2005; 12: 223-235.
21. Abonyi ME, Lakatos PL. Ribavirin in the treatment of hepatitis C. Anticancer Res. 2005; 25:1315-1320.
22. Zaman A, Fennerty MB, Keeffe EB. Systemic review: peginterferon vs standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther. 2003; 18: 661-670.
23. Lake-Bakaar G. Current and future therapy for chronic hepatitis C virus liver disease. Cur Drug Targ - Inf Dis. 2003; 3: 247-253.
24. Shiftman M, Zeuzem S, Diago M, et at. Natural history of chronic hepatitis C (CHC) in patients with persistently normal ALT levels in the multinational peginterferon alfa-2a (40 KD| (PEGASYS) plus ribavirin (COPEGUS) study: comparison of baseline histology with baseline data from patients with elevated ALT levels enrolled in phase III studies. Hepatology. 2004; 40 (Suppl. 1): 397.
25. Prati D, Shiftman M, Diago M, et al. How normal are normal alanine aminotransferase (ALT) levels in patients with chronic hepatitis C (CHC)? Data from the randomized, multinational peginterferon alfa-2a (40 KD) I PEGASYS | plus ribavirin (COPEGUS) trial in patients with persistently 'normal' ALT levels. Hepatology. 2004; 40 (Suppl. 1): 395.
26. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management and treatment of hepatitis C. Hepatology. 2004; 39:1147-1171.
27. Koike K, Kyoji M, Kimura S. Role of hepatitis C virus in the development of hepatocellular carcinoma: transgenic approach to viral hepatocar-cinogenesis. J Gastroenterol Hepatol. 2002; 17: 394-400.
28. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55: 1350-1359.
29. Caruntu FA, Benea L. Acute hepatitis C virus infection: diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis. 2006; 15: 249-256.
30. Heller T, Rehermann B. Acute hepatitis C: multifaceted disease. Semin Liver Dis. 2005; 25:7-17.
31. Palumbo E. PEG-interferon alfa-2b for acute hepatitis C: a review. Min Rev Med Chem. 2007; 7: 839-843.
32. Beltrami EM, Alvarado-Ramy F, Critchley SE, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50: 1-52.
33. Preboth M. United States Public Health Service. PHS guidelines for management of occupational exposure to HBV, HCV and HIV: HIV postexposure prophylaxis regimens. Am Fam Physician. 2002; 65: 324-325.